

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced
NEWS 16 FEB 19 New patent-examiner citations in 300,000 CA/CAplus
patent records provide insights into related prior
art
NEWS 17 FEB 19 Increase the precision of your patent queries -- use
terms from the IPC Thesaurus, Version 2009.01
NEWS 18 FEB 23 Several formats for image display and print options
discontinued in USPATFULL and USPAT2
NEWS 19 FEB 23 MEDLINE now offers more precise author group fields
and 2009 MeSH terms
NEWS 20 FEB 23 TOXCENTER updates mirror those of MEDLINE - more
precise author group fields and 2009 MeSH terms
NEWS 21 FEB 23 Three million new patent records blast AEROSPACE into
STN patent clusters
NEWS 22 FEB 25 USGENE enhanced with patent family and legal status
display data from INPADOCDB
NEWS 23 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display
formats

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:03:14 ON 09 MAR 2009

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 11:03:27 ON 09 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2009 HIGHEST RN 1116745-20-0

DICTIONARY FILE UPDATES: 6 MAR 2009 HIGHEST RN 1116745-20-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> E "THALIDOMIDE"/CN 25

E1	1	THALIDICINE/CN
E2	1	THALIDINE/CN
E3	1 -->	THALIDOMIDE/CN
E4	1	THALIDOMIDE-ASPIRIN MIXT./CN
E5	1	THALIDOMIDE-INDOMETHACIN MIXT./CN
E6	1	THALIDOMIDE-PREDNISOLONE MIXT./CN
E7	1	THALIDOMIDE-PREDNISONE MIXT./CN
E8	1	THALIDOXINE/CN
E9	1	THALIDOXINE ACETATE/CN
E10	1	THALIFABATINE/CN
E11	1	THALIFABERIDINE/CN
E12	1	THALIFABERINE/CN
E13	1	THALIFABINE/CN
E14	1	THALIFABOMINE/CN
E15	1	THALIFABORAMINE/CN
E16	1	THALIFALANDINE/CN
E17	1	THALIFARAMINE/CN

E18	1	THALIFARAPINE/CN
E19	1	THALIFARAZINE/CN
E20	1	THALIFARETINE/CN
E21	1	THALIFARICINE/CN
E22	1	THALIFAROLINE/CN
E23	1	THALIFARONINE/CN
E24	1	THALIFASINE/CN
E25	1	THALIFASINE DIACETATE/CN

=> S E3

L1 1 THALIDOMIDE/CN

=> DIS L1 1 SQIDE

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 50-35-1 REGISTRY
 CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phthalimide, N-(2,6-dioxo-3-piperidyl)- (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN (+)-Thalidomide
 CN α -(N-Phthalimido)glutarimide
 CN α -N-Phthalylglutaramide
 CN α -Phthalimidoglutaramide
 CN 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline
 CN 3-Phthalimidoglutaramide
 CN Celgene
 CN Contergan
 CN Distaval
 CN K 17
 CN Kevadon
 CN Myrin
 CN N-(2,6-Dioxo-3-piperidyl)phthalimide
 CN N-Phthaloylglutamimide
 CN Neurosedyn
 CN NSC 527179
 CN NSC 66847
 CN Pantosediv
 CN Pharmion
 CN Quetimid
 CN Sauramide
 CN Sedalis
 CN Sedoval
 CN Softenil
 CN Softenon
 CN Suaramide
 CN Talimol
 CN Talinol
 CN Thalidomide
 CN Thalomid
 DR 14088-68-7, 731-40-8
 MF C13 H10 N2 O4
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
 BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,
 CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS,
 IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS,
 PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE,
 TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)


DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent; Report

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3173 REFERENCES IN FILE CA (1907 TO DATE)
 199 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3180 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
8.36	8.58

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 11:04:46 ON 09 MAR 2009

FILE 'CAPLUS' ENTERED AT 11:04:46 ON 09 MAR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:04:46 ON 09 MAR 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 11:04:46 ON 09 MAR 2009

CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1

L2 8223 L1

=> s l1(P)("idiopathic pulmonary fibrosis")

L3 1 L1(P)("IDIOPATHIC PULMONARY FIBROSIS")

=> d l3

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:1198847 CAPLUS
 DN 146:55192
 TI Thalidomide reduces IL-18, IL-8 and TNF- α release from alveolar
 macrophages in interstitial lung disease
 AU Ye, Q.; Chen, B.; Tong, Z.; Nakamura, S.; Sarria, R.; Costabel, U.;
 Guzman, J.
 CS Dept of Pneumology and Allergology, Ruhrlandklinik, Medical Faculty,
 University of Essen, Essen, Germany
 SO European Respiratory Journal (2006), 28(4), 824-831
 CODEN: ERJOEI; ISSN: 0903-1936
 PB European Respiratory Society
 DT Journal
 LA English
 RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l1 and ("idiopathic pulmonary fibrosis")
 L4 13 L1 AND ("IDIOPATHIC PULMONARY FIBROSIS")

=> d l4 1-13 ibib, abs, hitstr

L4 ANSWER 1 OF 13 MEDLINE on STN
 ACCESSION NUMBER: 2008482983 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 18663075
 TITLE: Thalidomide inhibits the intractable cough of
 idiopathic pulmonary fibrosis.
 AUTHOR: Horton M R; Danoff S K; Lechtzin N
 SOURCE: Thorax, (2008 Aug) Vol. 63, No. 8, pp. 749.
 Journal code: 0417353. E-ISSN: 1468-3296.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: (CLINICAL TRIAL, PHASE II)
 Letter
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 (CLINICAL TRIAL)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200808
 ENTRY DATE: Entered STN: 30 Jul 2008
 Last Updated on STN: 26 Aug 2008
 Entered Medline: 25 Aug 2008

L4 ANSWER 2 OF 13 MEDLINE on STN
 ACCESSION NUMBER: 2007365137 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 17579094
 TITLE: Thalidomide prevents bleomycin-induced pulmonary fibrosis
 in mice.
 AUTHOR: Tabata Chiharu; Tabata Rie; Kadokawa Yoshio; Hisamori
 Shigeo; Takahashi Meiko; Mishima Michiaki; Nakano Takashi;
 Kubo Hajime
 CORPORATE SOURCE: Horizontal Medical Research Organization, Graduate School
 of Medicine, Kyoto University, Kyoto, Japan..
 ctatabata@hyo-med.ac.jp
 SOURCE: Journal of immunology (Baltimore, Md. : 1950), (2007 Jul 1)
 Vol. 179, No. 1, pp. 708-14.
 Journal code: 2985117R. ISSN: 0022-1767.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LANGUAGE: English
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 200708
ENTRY DATE: Entered STN: 21 Jun 2007
Last Updated on STN: 8 Aug 2007
Entered Medline: 7 Aug 2007

AB Pulmonary fibrosis in humans can occur as a result of a large number of conditions. In idiopathic pulmonary fibrosis (IPF), pulmonary function becomes progressively compromised resulting in a high mortality rate. Currently there are no proven effective treatments for IPF. We have recently reported that IL-6 and TGF-beta(1) plays an important role in proliferation and differentiation of lung fibroblasts, and all-trans-retinoic acid (ATRA) prevented bleomycin-induced lung fibrosis through the inhibition of these cytokines. Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis. In this study, we examined the preventive effect of Thal on bleomycin-induced pulmonary fibrosis in mice. We performed histological examinations and quantitative measurements of IL-6, TGF-beta(1), collagen type Ialpha1 (COL1A1), vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) in bleomycin-treated mouse lung tissues with or without the administration of Thal. Thal histologically ameliorated bleomycin-induced fibrosis in mouse lung tissues. Thal decreased the expressions of IL-6, TGF-beta(1), VEGF, Ang-1 Ang-2, and COL1A1 mRNA in mouse lung tissues. In addition, Thal inhibited angiogenesis in the lung. In vitro studies disclosed that Thal reduced 1) production of IL-6, TGF-beta(1), VEGF, Ang-1, and collagen synthesis from human lung fibroblasts, and 2) both IL-6-dependent proliferation and TGF-beta(1)-dependent transdifferentiation of the cells, which could be the mechanism underlying the preventive effect of Thal on pulmonary fibrosis. These data may provide a rationale to explore clinical use of Thal for the prevention of pulmonary fibrosis.

L4 ANSWER 3 OF 13 MEDLINE on STN
ACCESSION NUMBER: 2006581368 MEDLINE
DOCUMENT NUMBER: PubMed ID: 16837501
TITLE: Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease.
AUTHOR: Ye Q; Chen B; Tong Z; Nakamura S; Sarria R; Costabel U; Guzman J
CORPORATE SOURCE: Dept of Pneumology and Allergology, Ruhrlandklinik, Medical Faculty, University of Essen, Essen, Germany.
SOURCE: The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology, (2006 Oct) Vol. 28, No. 4, pp. 824-31. Electronic Publication: 2006-07-12.
Journal code: 8803460. ISSN: 0903-1936.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200702
ENTRY DATE: Entered STN: 3 Oct 2006
Last Updated on STN: 2 Feb 2007
Entered Medline: 1 Feb 2007

AB Thalidomide exhibits diverse actions of anti-inflammation, immunomodulation and anti-angiogenesis. The efficacy of thalidomide treatment in sarcoidosis with lupus pernio is thought to be due to inhibition of tumour necrosis factor (TNF)-alpha. The mechanisms that underlie the properties of thalidomide are still unclear in interstitial lung disease. The current authors investigated the potential inhibitory effects of thalidomide at concentrations of 0.1, 0.01 and 0.001 mM on the production of transforming growth factor-beta, TNF-alpha, interleukin

(IL)-1 β , IL-6, IL-8, IL-10, IL-12p70, IL-12p40 and IL-18 by alveolar macrophages from bronchoalveolar lavage in patients with sarcoidosis (n = 8), hypersensitivity pneumonitis (HP; n = 8) and idiopathic pulmonary fibrosis (IPF; n = 12). In sarcoidosis and HP patients, thalidomide induced a dose-dependent, partial suppression of lipopolysaccharide (LPS)-stimulated TNF- α , IL-12p40 and IL-18 release. At the highest thalidomide concentration (0.1 mM), LPS-stimulated IL-8 production was also suppressed. In IPF patients, although spontaneous production of TNF- α , IL-12p40, IL-18 and IL-8 was lower than in sarcoidosis and HP patients, with LPS stimulation the cytokines were significantly elevated and also partially inhibited by thalidomide. In conclusion, thalidomide has the potential to improve the therapeutic regimens for sarcoidosis, hypersensitivity pneumonitis and idiopathic pulmonary fibrosis by reducing tumour necrosis factor- α , interleukin-12p40, interleukin-18 and interleukin-8 production.

L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:659399 CAPLUS

DOCUMENT NUMBER: 147:63664

TITLE: Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice

AUTHOR(S): Tabata, Chiharu; Tabata, Rie; Kadokawa, Yoshio; Hisamori, Shigeo; Takahashi, Meiko; Mishima, Michiaki; Nakano, Takashi; Kubo, Hajime

CORPORATE SOURCE: Horizontal Medical Research Organization, Graduate School of Medicine, Kyoto University, Kyoto, Japan

SOURCE: Journal of Immunology (2007), 179(1), 708-714
CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Pulmonary fibrosis in humans can occur as a result of a large number of conditions. In idiopathic pulmonary fibrosis (IPF), pulmonary function becomes progressively compromised resulting in a high mortality rate. Currently there are no proven effective treatments for IPF. We have recently reported that IL-6 and TGF- β 1 plays an important role in proliferation and differentiation of lung fibroblasts, and all-trans-retinoic acid (ATRA) prevented bleomycin-induced lung fibrosis through the inhibition of these cytokines. Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis. In this study, we examined the preventive effect of Thal on bleomycin-induced pulmonary fibrosis in mice. We performed histol. exams. and quant. measurements of IL-6, TGF- β 1, collagen type I α 1 (COL1A1), vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) in bleomycin-treated mouse lung tissues with or without the administration of Thal. Thal histol. ameliorated bleomycin-induced fibrosis in mouse lung tissues. Thal decreased the expressions of IL-6, TGF- β 1, VEGF, Ang-1, Ang-2, and COL1A1 mRNA in mouse lung tissues. In addition, Thal inhibited angiogenesis in the lung. In vitro studies disclosed that Thal reduced (1) production of IL-6, TGF- β 1, VEGF, Ang-1, and collagen synthesis from human lung fibroblasts, and (2) both IL-6-dependent proliferation and TGF- β 1-dependent transdifferentiation of the cells, which could be the mechanism underlying the preventive effect of Thal on pulmonary fibrosis. These data may provide a rationale to explore clin. use of Thal for the prevention of pulmonary fibrosis.

IT 50-35-1, Thalidomide

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thalidomide prevents bleomycin-induced pulmonary fibrosis in mice)

RN 50-35-1 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidiny)- (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1198847 CAPLUS

DOCUMENT NUMBER: 146:55192

TITLE: Thalidomide reduces IL-18, IL-8 and TNF- α release from alveolar macrophages in interstitial lung disease

AUTHOR(S): Ye, Q.; Chen, B.; Tong, Z.; Nakamura, S.; Sarria, R.; Costabel, U.; Guzman, J.

CORPORATE SOURCE: Dept of Pneumology and Allergology, Ruhrlandklinik, Medical Faculty, University of Essen, Essen, Germany

SOURCE: European Respiratory Journal (2006), 28(4), 824-831
CODEN: ERJOEI; ISSN: 0903-1936

PUBLISHER: European Respiratory Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Thalidomide exhibits diverse actions of anti-inflammation, immunomodulation and anti-angiogenesis. The efficacy of thalidomide treatment in sarcoidosis with lupus pernio is thought to be due to inhibition of tumor necrosis factor (TNF)- α . The mechanisms that underlie the properties of thalidomide are still unclear in interstitial lung disease. The current authors investigated the potential inhibitory effects of thalidomide at concns. of 0.1, 0.01 and 0.001 mM on the production of transforming growth factor- β , TNF- α , interleukin (IL)-1 β , IL-6, IL-8, IL-10, IL-12p70, IL-12p40 and IL-18 by alveolar macrophages from bronchoalveolar lavage in patients with sarcoidosis (n = 8), hypersensitivity pneumonitis (HP; n = 8) and idiopathic pulmonary fibrosis (IPF; n = 12). In sarcoidosis and HP patients, thalidomide induced a dose-dependent, partial suppression of lipopolysaccharide (LPS)-stimulated TNF- α , IL-12p40 and IL-18 release. At the highest thalidomide concentration (0.1 mM), LPS-stimulated

IL-8 production was also suppressed. In IPF patients, although spontaneous production

of TNF- α , IL-12p40, IL-18 and IL-8 was lower than in sarcoidosis and HP patients, with LPS stimulation the cytokines were significantly elevated and also partially inhibited by thalidomide. In conclusion, thalidomide has the potential to improve the therapeutic regimens for sarcoidosis, hypersensitivity pneumonitis and idiopathic pulmonary fibrosis by reducing tumor necrosis factor- α , interleukin-12p40, interleukin-18 and interleukin-8 production


IT 50-35-1, Thalidomide

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(thalidomide reduced lipopolysaccharide stimulated tumor necrosis factor- α , interleukin-8, 12p40, 18, 8 production from alveolar macrophage in sarcoidosis, hypersensitivity pneumonitis and idiopathic pulmonary fibrosis patient)

RN 50-35-1 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2009:18342 USPATFULL

TITLE: COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS

INVENTOR(S): Schnapp, Lynn M., Seattle, WA, UNITED STATES
Choi, Jung-eun, Seoul, KOREA, REPUBLIC OF

PATENT ASSIGNEE(S): UNIVERSITY OF WASHINGTON, Seattle, WA, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090016967	A1	20090115
APPLICATION INFO.:	US 2008-124494	A1	20080521 (12)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-931139P	20070522 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NIXON PEABODY LLP - PATENT GROUP, 1100 CLINTON SQUARE, ROCHESTER, NY, 14604, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	3375	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Methods and compositions are provided for the treatment of acute lung injury and pulmonary fibrosis by administering inhibitors of IGF-1R signaling activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 50-35-1, Thalidomide
(compsns. comprising inhibitors of IGF-1R signaling activity and methods for treatment of respiratory disorders)

RN 50-35-1 USPATFULL

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)



L4 ANSWER 7 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2008:252747 USPATFULL
 TITLE: C5a Receptor Antagonists
 INVENTOR(S): Schnatbaum, Karsten, Berlin, GERMANY, FEDERAL REPUBLIC OF
 OF
 Scharn, Dirk, Berlin, GERMANY, FEDERAL REPUBLIC OF
 Locardi, Elsa, Berlin, GERMANY, FEDERAL REPUBLIC OF
 Polakowski, Thomas, Berlin, GERMANY, FEDERAL REPUBLIC OF
 OF
 Richter, Uwe, Berlin, GERMANY, FEDERAL REPUBLIC OF
 Reineke, Ulrich, Berlin, GERMANY, FEDERAL REPUBLIC OF
 Hummel, Gerd, Berlin, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): Jerini AG, Berlin, GERMANY, FEDERAL REPUBLIC OF
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080220003	A1	20080911
APPLICATION INFO.:	US 2006-915892	A1	20060530 (11)
	WO 2006-EP5141		20060530
			20071129 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2005-11620	20050530
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROTHWELL, FIGG, ERNST & MANBECK, P.C., 1425 K STREET, N.W., SUITE 800, WASHINGTON, DC, 20005, US	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	5308	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is related to a compound, preferably a C5a
 receptor antagonist, having the following structure, R1, R2, R3, R4, R5,
 R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20,
 R21 and R22 are individually and independently selected from the group
 comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl,
 alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl,
 heterocyclyl, substituted heterocyclyl, aryl, substituted aryl,
 heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl,
 heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted
 alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted
 arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro,
 cyano, acyl, substituted acyl, mercapto, alkylthio, substituted
 alkylthio, amino, substituted amino, alkylamino, substituted alkylamino,
 bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted
 cyclic amino, carbamoyl (--CONH.sub.2), substituted carbamoyl, carboxyl,
 carbamate, alkoxycarbonyl, substituted alkoxycarbonyl, acylamino,
 substituted acylamino, sulfamoyl (--SO.sub.2NH.sub.2), substituted
 sulfamoyl, haloalkyl, haloalkyloxy, --C(O)H, trialkylsilyl and azido.

##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 50-35-1, Thalidomide

(preparation of trisubstituted ureas as C5a receptor antagonists useful in
treatment and prevention of diseases)

RN 50-35-1 USPATFULL

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidiny)- (CA INDEX NAME)



L4 ANSWER 8 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2007:237682 USPATFULL

TITLE: Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases

INVENTOR(S): Zeldis, Jerome B., Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070208057	A1	20070906
APPLICATION INFO.:	US 2004-576138	A1	20041104 (10)
	WO 2004-US37083		20041104
			20070108 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-517405P	20031106 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1735	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of thalidomide alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of thalidomide. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 50-35-1, Thalidomide
(thalidomide for the treatment and management of cancers and other diseases.)

RN 50-35-1 USPATFULL

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinylo)- (CA INDEX NAME)



L4 ANSWER 9 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2007:61713 USPATFULL

TITLE: Nanocell drug delivery system
INVENTOR(S): Sengupta, Shiladitya, Waltham, MA, UNITED STATES
Zhao, Ganlin, Arlington, MA, UNITED STATES
Capila, Ishan, Ashland, MA, UNITED STATES
Eavarone, David, North Quincy, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070053845	A1	20070308
APPLICATION INFO.:	US 2006-495947	A1	20060728 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2005-70731, filed on 2 Mar 2005, PENDING		


	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-549280P	20040302 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CHOATE, HALL & STEWART LLP, TWO INTERNATIONAL PLACE, BOSTON, MA, 02110, US	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	2369	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianigenic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 50-35-1, Thalidomide
(nanometer liposomes containing two drugs in different part of the lipid layer for controlled delivery)
RN 50-35-1 USPATFULL
CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidiny1)- (CA INDEX NAME)



L4 ANSWER 10 OF 13 USPATFULL on STN
ACCESSION NUMBER: 2006:118381 USPATFULL
TITLE: Cannabinoid receptor ligands

INVENTOR(S): Shankar, Bandarpalle B., Branchburg, NJ, UNITED STATES
 Gilbert, Eric, Scotch Plains, NJ, UNITED STATES
 Rizvi, Razia K., Bloomfield, NJ, UNITED STATES
 Huang, Chunli, Springfield, NJ, UNITED STATES
 Kozlowski, Joseph A., Princeton, NJ, UNITED STATES
 McCombie, Stuart, Caldwell, NJ, UNITED STATES
 Shih, Neng-Yang, Warren, NJ, UNITED STATES
 PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060100228	A1	20060511
APPLICATION INFO.:	US 2005-157510	A1	20050621 (11)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-581837P	20040622 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2925	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of Formula I: ##STR1## and/or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions containing such compounds exhibit anti-inflammatory and immunomodulatory activity, and can be effective in treating cancer and inflammatory, immunomodulatory or respiratory diseases or conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 50-35-1, Thalidomide
 (co-administered agent; preparation of piperidine derivs. as cannabinoid receptor ligands co-administered with Thalidomide)
 RN 50-35-1 USPATFULL
 CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)



L4 ANSWER 11 OF 13 USPATFULL on STN
 ACCESSION NUMBER: 2005:248305 USPATFULL
 TITLE: HIF oligonucleotide decoy molecules
 INVENTOR(S): McEvoy, Leslie M., Mountain View, CA, UNITED STATES
 Powell, Lyn, San Mateo, CA, UNITED STATES
 Zhang, Jie, Campbell, CA, UNITED STATES
 Morris, Karen, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050215503	A1	20050929
APPLICATION INFO.:	US 2004-3907	A1	20041202 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-526869P	20031203 (60)
	US 2004-612406P	20040922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HELLER EHRMAN LLP, 275 MIDDLEFIELD ROAD, MENLO PARK, CA, 94025-3506, US	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	3021	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention concerns double-stranded HIF decoy oligodeoxynucleotide (dsODN) molecules comprising a core sequence that is capable of specific binding to a HIF transcription factor, compositions containing such molecules, and their use in the treatment of various diseases and pathologic conditions associated with the regulation of gene transcription by a HIF transcription factor.	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT	50-35-1, Thalidomide (aptamer oligodeoxynucleotide co-use with; development of HIF (hypoxia-inducible factor)-binding oligonucleotide aptamer decoy and its use in therapy of HIF-associated diseases)	
RN	50-35-1 USPTFULL	
CN	1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)	



L4 ANSWER 12 OF 13 USPTFULL on STN

ACCESSION NUMBER: 2005:37494 USPTFULL

TITLE: Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response

INVENTOR(S): Rojas, Mauricio, Atlanta, GA, UNITED STATES
Mora, Ana L., Atlanta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050032173	A1	20050210
APPLICATION INFO.:	US 2003-634645	A1	20030805 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TIM TINGKANG XIA, MORRIS, MANNING & MARTIN, LLP, 1600 ATLANTA FINANCIAL CENTER, 3343 PEACHTREE ROAD, N.E., ATLANTA, GA, 30326-1044		
NUMBER OF CLAIMS:	88		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	2205		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	An isolated fusion protein. In one embodiment of the present invention, the isolated fusion protein includes a membrane-translocating peptide sequence of about 8 to about 50 residues comprising at least eight		

consecutive residues of SEQ ID NO: 1
 (Ala-Ala-Val-Leu-Leu-Pro-Val-Leu-Leu-Ala-Ala-Pro), and an inhibitory
 IκB protein. Alternatively, the membrane-translocating sequence
 can have at least 9, 10, 11 or 12 twelve consecutive residues of SEQ ID
 NO: 1. The isolated infusion protein can be used to treat or prevent an
 immune response associated with an immune disorder or a disease or
 disorder related to apoptosis, such as cancer, in a host.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 50-35-1, Thalidomide

(fusion protein administered in combination with; fusion proteins with
 membrane translocating sequence (MTS) and using to inhibit immune
 response or disease related to apoptosis)

RN 50-35-1 USPATFULL

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)



L4 ANSWER 13 OF 13 USPATFULL on STN

ACCESSION NUMBER: 2002:12027 USPATFULL

TITLE: CD28-specific antibody compositions for use in methods
 of immunosuppression

INVENTOR(S): Yu, Xue-Zhong, Seattle, WA, UNITED STATES
 Anasetti, Claudio, Mercer Is., WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020006403	A1	20020117
APPLICATION INFO.:	US 2000-738546	A1	20001214 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-170857P	19991214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steven L. Highlander, Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701	
NUMBER OF CLAIMS:	66	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	3142	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for suppressing, reducing or even
 reversing an immune response. More particularly it concerns anti-CD28
 monoclonal antibody compositions and methods for preventing
 graft-versus-host disease (GVHD), transplant tissue rejection, and
 treating autoimmune diseases and the like. In particular embodiments, a
 method of inhibiting an immune response comprises administering an
 effective amount of a purified anti-CD28 antibody preparation to a
 subject, wherein the preparation modulates the CD28 receptor thereby
 inhibiting an immune response.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 50-35-1, Thalidomide

(CD28-specific antibody for immunosuppression and for treating
transplant rejection and autoimmune diseases)

RN 50-35-1 USPATFULL

CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 11:03:14 ON 09 MAR 2009)

FILE 'REGISTRY' ENTERED AT 11:03:27 ON 09 MAR 2009

E "THALIDOMIDE"/CN 25

L1 1 S E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 11:04:46 ON 09 MAR 2009

L2 8223 S L1

L3 1 S L1(P) ("IDIOPATHIC PULMONARY FIBROSIS")

L4 13 S L1 AND ("IDIOPATHIC PULMONARY FIBROSIS")

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	89.39	97.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.64	-1.64

STN INTERNATIONAL LOGOFF AT 11:07:24 ON 09 MAR 2009